Clinical professionals from all over Serbia gathered recently in the heart of Belgrade for a high-level seminar on statins. The event, held at the capital’s beautiful Old Court building, was a fitting backdrop for the launch of Actavis’ newest statin Atacor (atorvastatin), used in the treatment of hypercholesterolemia (the presence of high levels of cholesterol in the blood, a contributor to cardiovascular disease).

Atacor (atorvastatin), the generic equivalent of Pfizer's Lipitor®, efficiently regulates the blood cholesterol levels and is one of the most efficient drugs used in the therapy of primary hypercholesterolemia.

A number of expert speakers from the Clinical Centre of Serbia were invited to discuss the significance and advantages of statins for a range of conditions at the Actavis-sponsored seminar. Opening the proceedings was Professor Zorana Vasiljevic from the Institute for Cardiovascular Diseases (ICD), who explored the successful use of statins in treating arteriosclerosis of coronary arteries.

Also presenting were Professor Miloje Tomasevic from the ICD (discussing the pleotrophic effect of statins), Professor Nebojsa Lalic from the Institute for Endocrinology, Diabetes and Metabolic Disorders (the application of statins as part of Type II Diabetes treatment) and Professor Ljiljana Beslac-Bumbasirevic from Serbia’s Institute for Neurology (treatment outcomes on patients with aneurisms).